Twenty-six participants have completed treatment in our Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at planned Phase 3 sites across the United States and Canada. The purpose of this study is to provide the final training and provide supervision for our co-therapy teams. Study sites are now enrolling and 7 sites are fully enrolled. The study is expected to be completed in early 2019.
